oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Metformin increases AMP-activated-protein-kinase activity in skeletal of subjects with type 2 diabetes
Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Karolinska Institute, Centre of Gastrointestinal Disease, Ersta Hospital, Stockholm, Sweden.
Department of Surgery, Huddinge University Hospital, Huddinge, Sweden.
Show others and affiliations
2002 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 51, no 7, 2074-2081 p.Article in journal (Refereed) Published
Abstract [en]

Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK α2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK α2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK α2.

Place, publisher, year, edition, pages
Alexandra, VA, USA: American Diabetes Association Inc. , 2002. Vol. 51, no 7, 2074-2081 p.
National Category
Medical and Health Sciences Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-64078DOI: 10.2337/diabetes.51.7.2074ISI: 000176616200011PubMedID: 12086935Scopus ID: 2-s2.0-0036299982OAI: oai:DiVA.org:oru-64078DiVA: diva2:1173362
Note

Funding Agency:

NIAMS NIH HHS

Available from: 2018-01-12 Created: 2018-01-12 Last updated: 2018-01-16Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Authority records BETA

Ljungqvist, Olle

Search in DiVA

By author/editor
Ljungqvist, Olle
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Diabetes
Medical and Health SciencesEndocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 1 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf